Home | Publications | Therapeutic | Oncology place holder
place holder place holder

Oncology

Decoding Big Pharma's R&D Strategy in Oncology


Publication Date   September 2007
Publisher   Bioseeker
Product Type  
Pages   243
ISBN Number   not applicable
Product Code   BSK165
Ask a question about this product?

Price £1,665.00

approximately: $3,297 | €2,116

Summary


This report, Decoding Big Pharma's R&D Strategy in Oncology, is based on five major pharmaceutical companies in the oncology arena: Bristol-Myers Squibb, GlaxoSmithKline, Hoffmann-La Roche, and Sanofi-Aventis. Between them and together with their respective partners they have more than 250 drugs for the treatment of cancer. In other words, their collective R&D capacity and presence is solid enough to set trends for the entire field of oncology drug development. Beyond trends, all five are fiercely defining their competitive edge and advantage in oncology and that is what this report is about.

BioSeeker has in this very insightful publication focused on Deals and alliances, Drug targets, Compound types, Targeted therapy areas, and Selection of cancer indications among the five included big pharma companies. The collective force of the above research and analysis 'decodes' these five big pharma R&D efforts into strategy revealing and gap filing presentations. Enough to fuel and sustain comparative benchmarking, peer group surveillance, and partnership decisions.

Decoding Big Pharma's R&D Strategy in Oncology in numbers:

  • Includes references to more than 250 drugs and 600 clinical/preclinical trials
  • Addresses the competitive situation on more than 80 different cancer indications, including supportive care indications
  • Special focus on Angiogenesis-, Antibody-, Apoptosis-, Protein kinase inhibitor- and Vaccine drugs for the treatment of cancer
  • The included competitive landscape between the five big pharma includes more than 200 companies related to cancer drug development
  • Last five years of deals and alliances in oncology, including almost a hundred different key deals and alliances
  • Target analysis of 119 drug targets in oncology, including molecular function of target, target localization, type of compound for targeting, atargets affecting signaling pathways etc
  • Drug compound analysis by cancer indications

Content


  • 1 Executive Summary
  • 2 About Cancer Highlights
  • 3 Methodologies
  • 4 Table of Contents
    • 4.1 List of Tables
  • 5 Big Pharmas R&D Position and Strategy in Oncology: A Summary
    • 5.1 Bristol-Myers Squibb
    • 5.2 GlaxoSmithKline
    • 5.3 Hoffmann-La Roche
    • 5.4 Novartis
    • 5.5 Sanofi-Aventis
  • 6 Last Five Years of Deals and Alliances in Oncology
    • 6.1 Bristol Myers Squibb
      • 6.1.1 Discovery and Lead Molecule Improvements
      • 6.1.2 Adding Image Analysis to Support Clinical Trials and Early Diagnosis
      • 6.1.3 Bladder Cancer and Melanoma Registration Filings are Emminent
      • 6.1.4 The Human Kinome and Cell Cycle Inhibitors
      • 6.1.5 Strategic Priorities in Pipeline Development Leads to Divestments
      • 6.1.6 Erbitux Expansion is Set to Challenge Avastin
    • 6.2 GlaxoSmithKline
      • 6.2.1 The Biopharmaceutical Strategy at GSK
      • 6.2.2 Out Goes Classes of Small Molecule Inhibitors
      • 6.2.3 Marketing and Manufacturing Collaborations
      • 6.2.4 Patient Selectionfo r GSKs Targeted Cancer Therapies
      • 6.2.5 GSK Taping Into Knowledge Databases
      • 6.2.6 Increasing the Oral Bioavailability Cytotoxic Oncology Drugs
      • 6.2.7 Oxford University Helps GSK in India
      • 6.2.8 GSK is Set to Improve Medical Imaging
    • 6.3 Hoffmann-La Roche
      • 6.3.1 Roche Builds Center of Excellence for RNAi Therapeutics Discovery
      • 6.3.2 A New Delivery Route for Avastin?
      • 6.3.3 Improving Antibody Drugs
      • 6.3.4 Roche Strengthens Presence in Genomics Research Market
      • 6.3.5 Target Validation
      • 6.3.6 Drug Discovery Collaborations
      • 6.3.7 Marketing
      • 6.3.8 Outlicensing
      • 6.3.9 Size Doesnt Matter: Genentech's Goal of Aggressively Pursuing Novel and Innovative Therapies
    • 6.4 Novartis
      • 6.4.1 Novartis Acquisition of Chiron: A Major Biopharmaceutical Investment
      • 6.4.2 Protein Kinase Inhibitors
      • 6.4.3 Next Generation Oral Topoisomerase Inhibitor and Telomerase Promotors
      • 6.4.4 Novartis Sells of World-Wide Rights
      • 6.4.5 Biomarker and Proteomics Research
    • 6.5 Sanofi-Aventis
      • 6.5.1 Target Screening and Validation
      • 6.5.2 Biologicals
      • 6.5.3 A Short Cut to Success?
      • 6.5.4 Aventis Divests Interest
      • 6.5.5 Recombine My Molecule
  • 7 Competitive R&D Comparison on Oncology Drug Target Level
    • 7.1 Target Overview
    • 7.2 Head to Head Target Comparison by Molecular Function and Cancer Type
      • 7.2.1 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets
      • 7.2.2 Receptor Activity Targets
      • 7.2.3 G-protein Coupled Receptor Activity Targets
      • 7.2.4 Protein Serine/Threonine Kinase Activity Targets
      • 7.2.5 Transcription Factor Activity Targets
      • 7.2.6 Transmembrane Receptor Activity Targets
      • 7.2.7 Catalytic Activity Targets
      • 7.2.8 Cytokine Activity Targets
      • 7.2.9 Protein-Tyrosine Kinase Activity Targets
      • 7.2.10 Kinase Activity Targets
      • 7.2.11 DNA Topoisomerase Activity Targets
  • 4 Decoding Big Pharmas R&D Strategy in Oncology
  • 10 Cancer Highlights No 4#2007| BioSeeker Group AB c
      • 7.2.12 Growth Factor Activity Targets
      • 7.2.13 Ligase Activity Targets
      • 7.2.14 Motor Activity Targets
      • 7.2.15 Structural Constituent of Cytoskeleton Targets
      • 7.2.16 Transporter Activity Targets
      • 7.2.17 Targets According to Miscellaneous Molecular Function Groups
      • 7.2.18 Unclassified or Unknown Molecular Function of Targets
    • 7.3 Drug Targets by Target Localization and Compound Type
    • 7.4 Targets, Drugs and Cancer Indications Linked to Signaling Pathways
      • 7.4.1 Alpha6 Beta4 Integrin Signaling Pathway
      • 7.4.2 Androgen Receptor Signaling Pathway
      • 7.4.3 B Cell Receptor Signaling Pathway
      • 7.4.4 EGFR1 Signaling Pathway
      • 7.4.5 Hedgehog Signaling Pathway
      • 7.4.6 ID Signaling Pathway
      • 7.4.7 IL-1 Signaling Pathway
      • 7.4.8 IL-2 Signaling Pathway
      • 7.4.9 IL-3 Signaling Pathway
      • 7.4.10 IL-4 Signaling Pathway
      • 7.4.11 IL-5 Signaling Pathway
      • 7.4.12 IL-6 Signaling Pathway
      • 7.4.13 IL-9 Signaling Pathway
      • 7.4.14 Kit Receptor Signaling Pathway
      • 7.4.15 Notch Signaling Pathway
      • 7.4.16 T Cell Receptor Signaling Pathway
      • 7.4.17 TGF-beta Receptor Signaling Pathway
      • 7.4.18 TNF-alpha Signaling Pathway
      • 7.4.19 Wnt Signaling Pathway
  • 8 Drug Compound Type Analysis
    • 8.1 Deployment of Biological Based Compounds by Cancer Indications
    • 8.2 Deployment of Chemical Based Compounds by Cancer Indications
    • 8.3 Deployment of Natural Product Compounds by Cancer Indications
  • 9 Drug Development in Oncology by Major Targeted Therapy Areas
    • 9.1 Angiogenesis
    • 9.2 Antibodies
    • 9.3 Apoptosis
    • 9.4 Protein Kinase Inhibitors
    • 9.5 Vaccines
  • 10 Cancer Indication Focus Analysis
    • 10.1 Preclinical Stage Pipeline
    • 10.2 Phase I Clinical Stage Pipeline
    • 10.3 Phase II Clinical Stage Pipeline
    • 10.4 Phase III Clinical Stage Pipeline
    • 10.5 Drugs Soon to be on the Market
    • 10.6 Approved Drugs
  • 11 Disclaimer
  • 12 Drug Index
  • 13 Company Index
  • List of Tables
    • Table 1: How to Navigate the Report
    • Table 2: Number of Pursued Oncology Drugs Targets by Company
    • Table 3: Pursued Oncology Drugs Targets by Molecular Function
    • Table 4: Drug Target Expression Profiles in Humans
    • Table 5: Identified Targets By Cancer Indications
    • Table 6: Head to Head Comparison of Drugs with Transmembrane Receptor Protein Tyrosine Kinase Activity Targets
    • Table 7: Head to Head Comparison of Drugs with Receptor Activity Targets
    • Table 8: Head to Head Comparison of Drugs with G-protein Coupled Receptor Activity
    • Table 9: Head to Head Comparison of Drugs with Protein Serine/Threonine Kinase Activity
    • Table 10: Head to Head Comparison of Drugs with Transcription Factor Activity Targets
    • Table 11: Head to Head Comparison of Drugs with Transmembrane Receptor Activity Targets
    • Table 12: Head to Head Comparison of Drugs with Catalytic Activity Targets
    • Table 13: Head to Head Comparison of Drugs with Cytokine Activity Targets 4 Decoding Big Pharmas R&D Strategy in Oncology 12 Cancer Highlights No 4#2007| BioSeeker Group AB c
    • Table 14: Head to Head Comparison of Drugs with Protein-Tyrosine Kinase Activity Targets
    • Table 15: Head to Head Comparison of Drugs with Kinase Activity Targets
    • Table 16: Head to Head Comparison of Drugs with DNA Topoisomerase Activity Targets
    • Table 17: Head to Head Comparison of Drugs with Growth Factor Activity Targets
    • Table 18: Head to Head Comparison of Drugs with Ligase Activity Targets
    • Table 19: Head to Head Comparison of Drugs with Motor Activity Targets
    • Table 20: Head to Head Comparison of Drugs with Structural Constituent of Cytoskeleton Targets
    • Table 21: Head to Head Comparison of Drugs with Transporter Activity Targets
    • Table 22: Head to Head Comparison of Drugs with Targets According to Miscellaneous Molecular Function groups
    • Table 23: Head to Head Comparison of Drugs with Unclassified or Unknown Molecular Function Targets
    • Table 24: Drug Target Comparison by Target Localization and Compound Type
    • Table 25: Targeting Signaling Pathways: An Overview
    • Table 26: Targeted Signaling Pathway Profiles of Big Pharma
    • Table 27: Targets, Drugs and Cancer Indications Linked to the Alpha6 Beta4 Integrin Signaling Pathway
    • Table 28: Targets, Drugs and Cancer Indications Linked to the Androgen Receptor Signaling Pathway
    • Table 29: Targets, Drugs and Cancer Indications Linked to the B Cell Receptor Signaling Pathway
    • Table 30: Targets, Drugs and Cancer Indications Linked to the EGFR1 Signaling Pathway
    • Table 31: Targets, Drugs and Cancer Indications Linked to the Hedgehog Signaling Pathway
    • Table 32: Targets, Drugs and Cancer Indications Linked to the ID Signaling Pathway
    • Table 33: Targets, Drugs and Cancer Indications Linked to the IL-1 Signaling Pathway
    • Table 34: Targets, Drugs and Cancer Indications Linked to the IL-3 Signaling Pathway
    • Table 35: Targets, Drugs and Cancer Indications Linked to the IL-4 Signaling Pathway
    • Table 36: Targets, Drugs and Cancer Indications Linked to the IL-5 Signaling Pathway
    • Table 37: Targets, Drugs and Cancer Indications Linked to the IL-6 Signaling Pathway
    • Table 38: Targets, Drugs and Cancer Indications Linked to the Kit Receptor Signaling Pathway
    • Table 39: Targets, Drugs and Cancer Indications Linked to the Notch Signaling Pathway
    • Table 40: Targets, Drugs and Cancer Indications Linked to the T Cell Receptor Signaling Pathway
    • Table 41: Targets, Drugs and Cancer Indications Linked to the TGF-beta Receptor Signaling Pathway
    • Table 42: Targets, Drugs and Cancer Indications Linked to the TNF-alpha Signaling Pathway
    • Table 43: Targets, Drugs and Cancer Indications Linked to the Wnt Signaling Pathway
    • Table 44: Deployment of Biological Based Compounds by Cancer Indications
    • Table 45: Deployment of Chemical Based Compounds by Cancer Indications
    • Table 46: Deployment of Natural Product Based Compounds by Cancer Indications
    • Table 47: Comparative Presentation of Targeted Therapy Areas in Oncology
    • Table 48: The Angiogenesis Pipeline by Cancer Type and Developmental Stage
    • Table 49: The Antibody Pipeline by Cancer Type and Developmental Stage
    • Table 50: The Apoptosis Pipeline by Cancer Type and Developmental Stage
    • Table 51: The Protein Kinase Inhibitor Pipeline by Cancer Type and Developmental Stage
    • Table 52: The Cancer Vaccine Pipeline by Cancer Type and Developmental Stage
    • Table 53: Summary of Big Pharmas Preclinical Stage Pipeline
    • Table 54: Preclinical Stage Pipeline by Cancer Indications
    • Table 55: Summary of Big Pharmas Phase I Clinical Stage Pipeline
    • Table 56: : Phase I Clinical Stage Pipeline by Cancer Indications
    • Table 57: Summary of Big Pharmas Phase II Clinical Stage Pipeline
    • Table 58: Phase II Clinical Stage Pipeline by Cancer Indications
    • Table 59: Summary of Big Pharmas Phase III Clinical Stage Pipeline
    • Table 60: Phase III Clinical Stage Pipeline by Cancer Indications
    • Table 61: Oncology Drugs Soon to be on the Market
    • Table 62: Summary of Big Pharmas Approved Oncology Drugs
    • Table 63: Approved Drugs by Cancer Indications